Table 2 |
|||||||||||
|
Genotype distribution of BOSpos and BOSneg patients and healthy controlsa |
|||||||||||
|
BOSpos (n = 20) |
BOSneg (n = 87)b |
Controls (n = 422) |
|||||||||
|
SNPs |
Gene region |
Major/minor |
AA |
AB |
BB |
AA |
AB |
BB |
AA |
AB |
BB |
|
|
|||||||||||
|
rs12154695 |
Unknown |
C/A |
12 (60) |
6 (30) |
2 (10) |
34 (39) |
47 (54) |
6 (7) |
181 (43) |
189 (45) |
52 (12) |
|
rs10256914 |
Intron |
T/C |
12 (60) |
6 (30) |
2 (10) |
50 (57) |
29 (33) |
8 (9) |
228 (54) |
158 (37) |
36 (9) |
|
rs3807989c |
Intron |
C/T |
4 (20) |
9 (45) |
7 (35) |
33 (38) |
47 (54) |
7 (8) |
144 (34) |
206 (49) |
72 (17) |
|
rs3807994 |
Intron |
C/T |
10 (50) |
7 (35) |
3 (15) |
57 (66) |
28 (32) |
2 (2) |
240 (57) |
156 (37) |
26 (6) |
|
|
|||||||||||
|
aAll data are n (%). BOSpos, bronchiolitis obliterans syndrome-positive; BOSneg, bronchiolitis obliterans syndrome-negative; A, major; B, minor. bCAV1 genotyping failed in three BOSneg patients. cGenotype distribution BOSpos vs BOSneg: P = 0.015; allele frequency BOSpos vs BOSneg: P = 0.027. |
|||||||||||
|
Kastelijn et al. Fibrogenesis & Tissue Repair 2011 4:24 doi:10.1186/1755-1536-4-24 |
|||||||||||
